Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
YH003 / Biocytogen
NCT05420324: A Study to Assess YH003 in Combination With Pebolizumab and Albumin Paclitaxel Injection in Subjects With Unresectable/Metastatic Mucosal Melanoma	Recruiting	2	43	RoW	YH003, Pembrolizumab, albumin paclitaxel	Eucure (Beijing) Biopharma Co., Ltd	Mucosal Melanoma	12/23	09/25
YH003004, NCT05031494: A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers	Active, not recruiting	2	129	US, RoW	YH003, Toripalimab, Nab-paclitaxel, Gemcitabine	Eucure (Beijing) Biopharma Co., Ltd	Melanoma, Pancreatic Ductal Adenocarcinoma	01/24	01/24
NCT05017623: A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors	Completed	1	10	RoW	YH003	Eucure (Beijing) Biopharma Co., Ltd	Advanced Solid Tumors	03/23	03/23
NCT05176509: A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects With Advanced Solid Tumors	Recruiting	1	44	RoW	YH003, YH001, Pembrolizumab	Eucure (Beijing) Biopharma Co., Ltd	Solid Tumor	12/23	12/24